CL2022001079A1 - Métodos y composiciones para el tratamiento del síndrome de rett - Google Patents
Métodos y composiciones para el tratamiento del síndrome de rettInfo
- Publication number
- CL2022001079A1 CL2022001079A1 CL2022001079A CL2022001079A CL2022001079A1 CL 2022001079 A1 CL2022001079 A1 CL 2022001079A1 CL 2022001079 A CL2022001079 A CL 2022001079A CL 2022001079 A CL2022001079 A CL 2022001079A CL 2022001079 A1 CL2022001079 A1 CL 2022001079A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- rett syndrome
- compositions
- treatment
- trofinetide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Detergent Compositions (AREA)
- Chemical Or Physical Treatment Of Fibers (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962927008P | 2019-10-28 | 2019-10-28 | |
| US202063031201P | 2020-05-28 | 2020-05-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022001079A1 true CL2022001079A1 (es) | 2023-04-21 |
Family
ID=75715568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022001079A CL2022001079A1 (es) | 2019-10-28 | 2022-04-28 | Métodos y composiciones para el tratamiento del síndrome de rett |
Country Status (14)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023287750A1 (en) | 2021-07-12 | 2023-01-19 | Acadia Pharmaceuticals Inc. | Crystalline forms of trofinetide |
| WO2023242844A1 (en) * | 2022-06-15 | 2023-12-21 | Ramot At Tel-Aviv University Ltd. | Method and therapeutic agent for treatment of disease or disorder associated with impaired firing rate and/or mitochondrial calcium homeostasis |
| WO2025262646A1 (en) * | 2024-06-22 | 2025-12-26 | Biophore India Pharmaceuticals Pvt. Ltd | Dosage forms of trofinetide and its pharmaceutically acceptable salt thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6709817B1 (en) * | 1999-09-07 | 2004-03-23 | Baylor College Of Medicine | Method of screening Rett syndrome by detecting a mutation in MECP2 |
| LT2667715T (lt) * | 2011-01-27 | 2017-11-10 | Neuren Pharmaceuticals Limited | Autizmo spektro susirgimų gydymas, naudojant glicil-l-2-metilprolil-l-glutamo rūgštį |
| CN105358160A (zh) * | 2013-02-20 | 2016-02-24 | 瑟阿瓦斯克公司 | 亚硝酸盐的药物制剂及其用途 |
| SI3024463T1 (sl) * | 2013-07-25 | 2020-08-31 | Neuren Pharmaceuticals Limited | Nevroprotektivne biciklične spojine in postopki za njihovo uporabo pri zdravljenju motenj avtističnega spektra in nevrorazvojnih motenj |
| US20150224164A1 (en) * | 2013-11-26 | 2015-08-13 | Neuren Pharmaceuticals Limited | Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid |
| GB2554064B (en) * | 2016-09-01 | 2019-11-20 | Jit Singh Shailinder | An enteral feeding tube |
-
2020
- 2020-10-28 KR KR1020227018117A patent/KR20220106982A/ko active Pending
- 2020-10-28 WO PCT/US2020/057627 patent/WO2021086892A1/en not_active Ceased
- 2020-10-28 JP JP2022552123A patent/JP2022553888A/ja active Pending
- 2020-10-28 AU AU2020376801A patent/AU2020376801A1/en active Pending
- 2020-10-28 CA CA3156680A patent/CA3156680A1/en active Pending
- 2020-10-28 CN CN202080090500.2A patent/CN115335071A/zh active Pending
- 2020-10-28 TW TW109137417A patent/TW202116300A/zh unknown
- 2020-10-28 MX MX2022004785A patent/MX2022004785A/es unknown
- 2020-10-28 EP EP20883589.2A patent/EP4051308A4/en active Pending
- 2020-10-28 IL IL292617A patent/IL292617B2/en unknown
- 2020-10-28 BR BR112022008095A patent/BR112022008095A2/pt unknown
-
2022
- 2022-02-01 US US17/590,496 patent/US20220339138A1/en active Pending
- 2022-04-28 CL CL2022001079A patent/CL2022001079A1/es unknown
- 2022-05-31 CO CONC2022/0007501A patent/CO2022007501A2/es unknown
-
2025
- 2025-07-10 JP JP2025116586A patent/JP2025148461A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025148461A (ja) | 2025-10-07 |
| AU2020376801A1 (en) | 2022-06-09 |
| IL292617B1 (en) | 2025-11-01 |
| WO2021086892A1 (en) | 2021-05-06 |
| BR112022008095A2 (pt) | 2022-07-12 |
| TW202116300A (zh) | 2021-05-01 |
| CA3156680A1 (en) | 2021-05-06 |
| US20220339138A1 (en) | 2022-10-27 |
| IL292617A (en) | 2022-07-01 |
| CO2022007501A2 (es) | 2022-08-30 |
| EP4051308A4 (en) | 2023-08-23 |
| EP4051308A1 (en) | 2022-09-07 |
| IL292617B2 (en) | 2026-03-01 |
| KR20220106982A (ko) | 2022-08-01 |
| JP2022553888A (ja) | 2022-12-26 |
| CN115335071A (zh) | 2022-11-11 |
| MX2022004785A (es) | 2022-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022007501A2 (es) | Métodos y composiciones para el tratamiento del síndrome de rett | |
| CL2021001292A1 (es) | Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres | |
| MX2023000735A (es) | Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer. | |
| MX2021013788A (es) | Dosificación del inhibidor de kras para el tratamiento de cánceres. | |
| MX2020004467A (es) | Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r. | |
| CL2022001743A1 (es) | Dosis de gamma-hidroxibutirato (ghb) | |
| MX2017000628A (es) | Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia. | |
| CY1124532T1 (el) | Δοσολογικα σχηματα για συζευγματα φαρμακου-αντισωματος αντι-tf | |
| CR20170424A (es) | Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la cápsula del vhb | |
| MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
| CL2021000924A1 (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| CO2018004776A2 (es) | Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana | |
| CO2019007409A2 (es) | Derivados de la pirimidin enona tricíclica para la inhibición de rorγ y otros usos | |
| MX2020004513A (es) | Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican. | |
| MX388408B (es) | Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv | |
| EA202191165A1 (ru) | Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы | |
| CL2020000270A1 (es) | Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf. | |
| MX2016013245A (es) | Regimen de dosificacion de liberacion inmediata de moduladores s1p. | |
| CL2020000508A1 (es) | Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos. | |
| MX2019015207A (es) | Compuestos para tratar el cancer de ovario. | |
| MX2023012640A (es) | Uso de profarmacos de riluzol para tratar ataxias. | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| AR103118A1 (es) | Tratamientos médicos basados en anamorelina | |
| MX2020007760A (es) | Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano. | |
| CL2021001635A1 (es) | Tratamiento combinado para tumores sólidos con docetaxel y un inhibidor de cyp3a |